Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Benchmark Statement Prosthetics and Orthotics Services in Lebanon



Lebanese, Syrian and Palestinian people with physical disabilities living in Lebanon are confronted with a variety of barriers that hinder their access to healthcare services especially, rehabilitation services, which include prosthetic and orthotic devices. Furthermore, the absence of a unified and standardized prosthetic and orthotic coverage procedure makes access even more difficult for those individuals.
 
Therefore, the International Committee of Red Cross (ICRC) in Lebanon has worked in close partnership with the Lebanese Ministry of Public Health (MoPH), Lebanese Syndicate of Prosthetics and Orthotics and University of Balamand, with the support of the Rehabskills Limited team, to complete a Benchmark Statement on the Prosthetics and Orthotics Sector in Lebanon (English version).
 
The Benchmark Statement aims at comparing the situation in Lebanon with the World Health Organization (WHO) Standards for Prosthetics and Orthotics as well as making recommendations for its improvement. Consequently, the Benchmark Statement provides a strong foundation that will enable the upgrade of this sector therefore, leading to the establishment of a national strategy for 2030 and regulation of the profession. The Statement covers four main areas of the health system (also known as the four “Ps”): Policy; Products; Personnel and Provision of services. The vision, mission and aims of each ‘P’ will be incorporated into training and mentoring packages that will enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
In April 2021, the ICRC and project partners organized, in collaboration with the Disability Hub, the first online webinar focusing on the Policy area in order to reinforce the visibility and promote the dissemination of the project. The webinar successfully attracted a big number of participants, at a time when health services and systems were and still are severely disrupted in the country due to the Beirut blast, the Covid pandemic, and of course the deteriorating economic situation and political deadlock.



Throughout this year and in 2022, other related online webinars will be organized by the ICRC and project partners to enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
Despite all the difficulties and challenges, Lebanon has taken the first steps on the path of aligning itself with the relevant WHO standards by undertaking this benchmarking process thus, highlighting  its commitment to working towards transforming and improving the provision of prosthetic and orthotic services in the country.
    ...
    7
    ...
ATC Name B/G Ingredients Dosage Form Price
M05BA07 APO-RISEDRONATE G Risedronate sodium - 150mg 150mg Tablet 1,034,759 L.L
C07BB03 ATONIUM PLUS G Chlortalidone - 25mg, Atenolol - 50mg Tablet 738,473 L.L
M05BB03 ACIDE ALENDRONIQUE/ VITAMINE D3 BGR G Alendronic acid - 70mg, Colecalciferol - 5600UI Tablet 815,712 L.L
C07BB03 ATONIUM PLUS G Chlortalidone - 25mg, Atenolol - 100mg Tablet 738,473 L.L
D01BA02 APO-TERBINAFINE G Terbinafine HCl - 250mg 250mg Tablet 1,409,691 L.L
C08CA01 AMLO TAD G Amlodipine besylate - 5mg 5mg Tablet 744,489 L.L
C08CA01 AMLOCARD G Amlodipine (besylate) - 5mg 5mg Tablet 473,545 L.L
N05BA12 ALPROX G Alprazolam - 0.5mg 0.5mg Tablet 383,955 L.L
C08CA01 AMLOCOEUR G Amlodipine - 5mg 5mg Tablet 362,198 L.L
P02CA03 ALBENDA G Albendazole - 200mg 200mg Tablet 116,914 L.L
P02CA03 ALBENDAZOLE-UBSA G Albendazole - 200mg 200mg Tablet 127,985 L.L
N05BA12 ALPROX G Alprazolam - 1mg 1mg Tablet 895,895 L.L
C08CA01 AMLORINE 5 G Amlodipine (besylate) - 5mg 5mg Tablet 388,370 L.L
J05AF10 APO-ENTECAVIR G Entecavir - 0.5mg 0.5mg Tablet 28,943,287 L.L
C08CA01 AMLINE G Amlodipine - 10mg 10mg Tablet 662,962 L.L
C08CA01 AMLOCARD 10 G Amlodipine (besylate) - 10mg 10mg Tablet 870,298 L.L
L01EA01 APO-IMATINIB G Imatinib - 100mg 100mg Tablet 38,330,537 L.L
A10BB12 AMARYL B Glimepiride - 1mg 1mg Tablet 231,141 L.L
C08CA01 AMLOKEY G Amlodipine (besylate) - 10mg 10mg Tablet 397,777 L.L
A10BB12 AMEPRIDE G Glimepiride - 1mg 1mg Tablet 137,072 L.L
C08CA01 AMLORINE 10 G Amlodipine (besylate) - 10mg 10mg Tablet 959,504 L.L
M01AB16 ACECLOFAR G Aceclofenac - 100mg 100mg Tablet 131,697 L.L
A10BB12 AMARYL B Glimepiride - 2mg 2mg Tablet 233,829 L.L
A10BB12 AMEPRIDE G Glimepiride - 2mg 2mg Tablet 139,760 L.L
C09DX01 ARBITEN AM PLUS G Valsartan - 160mg, Amlodipine - 5mg, Hydrochlorothiazide - 12.5mg Tablet 857,372 L.L
L01EA02 APO-DASATINIB G Dasatinib - 70mg 70mg Tablet 71,323,688 L.L
L01EA02 APO-DASATINIB G Dasatinib - 50mg 50mg Tablet 71,323,688 L.L
A10BB12 AMARYL B Glimepiride - 3mg 3mg Tablet 392,402 L.L
A10BB12 AMEPRIDE G Glimepiride - 3mg 3mg Tablet 215,015 L.L
C01BD01 AMIODARONE BIOGARAN G Amiodarone (HCl) - 200mg 200mg Tablet 345,368 L.L
    ...
    7
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025